Shinde S, Bigogno C, Simmons A, Kathuria N, Ghose A, Apte V
Heliyon. 2025; 11(3):e42054.
PMID: 39927143
PMC: 11804570.
DOI: 10.1016/j.heliyon.2025.e42054.
Sintusek P, Phewplung T, Sanpavat A, Poovorawan Y
World J Gastrointest Oncol. 2021; 13(11):1680-1695.
PMID: 34853643
PMC: 8603454.
DOI: 10.4251/wjgo.v13.i11.1680.
Tang Y, Kong Y
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2021; 50(4):514-523.
PMID: 34704422
PMC: 8777462.
DOI: 10.3724/zdxbyxb-2021-0255.
Li S, Saviano A, Erstad D, Hoshida Y, Fuchs B, Baumert T
J Clin Med. 2020; 9(12).
PMID: 33255794
PMC: 7760293.
DOI: 10.3390/jcm9123817.
van Ginkel W, Rodenburg I, Harding C, Hollak C, Heiner-Fokkema M, van Spronsen F
Paediatr Drugs. 2019; 21(6):413-426.
PMID: 31667718
PMC: 6885500.
DOI: 10.1007/s40272-019-00364-4.
GSTZ1 deficiency promotes hepatocellular carcinoma proliferation via activation of the KEAP1/NRF2 pathway.
Li J, Wang Q, Yang Y, Lei C, Yang F, Liang L
J Exp Clin Cancer Res. 2019; 38(1):438.
PMID: 31666108
PMC: 6822483.
DOI: 10.1186/s13046-019-1459-6.
GSTZ1-1 Deficiency Activates NRF2/IGF1R Axis in HCC via Accumulation of Oncometabolite Succinylacetone.
Yang F, Li J, Deng H, Wang Y, Lei C, Wang Q
EMBO J. 2019; 38(15):e101964.
PMID: 31267557
PMC: 6669923.
DOI: 10.15252/embj.2019101964.
Update in global trends and aetiology of hepatocellular carcinoma.
Rawla P, Sunkara T, Muralidharan P, Raj J
Contemp Oncol (Pozn). 2018; 22(3):141-150.
PMID: 30455585
PMC: 6238087.
DOI: 10.5114/wo.2018.78941.
The association between chemical-induced porphyria and hepatic cancer.
Smith A, Foster J
Toxicol Res (Camb). 2018; 7(4):647-663.
PMID: 30090612
PMC: 6060669.
DOI: 10.1039/c8tx00019k.
Hepatocellular Carcinoma: Causes, Mechanism of Progression and Biomarkers.
Singh A, Kumar R, Pandey A
Curr Chem Genom Transl Med. 2018; 12:9-26.
PMID: 30069430
PMC: 6047212.
DOI: 10.2174/2213988501812010009.
Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations.
Chinsky J, Singh R, Ficicioglu C, van Karnebeek C, Grompe M, Mitchell G
Genet Med. 2017; 19(12).
PMID: 28771246
PMC: 5729346.
DOI: 10.1038/gim.2017.101.
Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1).
Das A
Appl Clin Genet. 2017; 10:43-48.
PMID: 28769581
PMC: 5533484.
DOI: 10.2147/TACG.S113310.
Case of hepatocellular carcinoma in a patient with hereditary tyrosinemia in the post-newborn screening era.
Imseis E, Bynon J, Thornhill C
World J Hepatol. 2017; 9(9):487-490.
PMID: 28396719
PMC: 5368626.
DOI: 10.4254/wjh.v9.i9.487.
Altered metabolite levels in cancer: implications for tumour biology and cancer therapy.
Sullivan L, Gui D, Vander Heiden M
Nat Rev Cancer. 2016; 16(11):680-693.
PMID: 27658530
DOI: 10.1038/nrc.2016.85.
Liver tumors in children with metabolic disorders.
Schady D, Roy A, Finegold M
Transl Pediatr. 2016; 4(4):290-303.
PMID: 26835391
PMC: 4728996.
DOI: 10.3978/j.issn.2224-4336.2015.10.08.
Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice.
Mayorandan S, Meyer U, Gokcay G, Garcia Segarra N, de Baulny H, van Spronsen F
Orphanet J Rare Dis. 2014; 9:107.
PMID: 25081276
PMC: 4347563.
DOI: 10.1186/s13023-014-0107-7.
Heat shock response associated with hepatocarcinogenesis in a murine model of hereditary tyrosinemia type I.
Angileri F, Morrow G, Roy V, Orejuela D, Tanguay R
Cancers (Basel). 2014; 6(2):998-1019.
PMID: 24762634
PMC: 4074813.
DOI: 10.3390/cancers6020998.
Early nitisinone treatment reduces the need for liver transplantation in children with tyrosinaemia type 1 and improves post-transplant renal function.
Bartlett D, Lloyd C, McKiernan P, Newsome P
J Inherit Metab Dis. 2014; 37(5):745-52.
PMID: 24515874
DOI: 10.1007/s10545-014-9683-x.
HBV induced HCC: major risk factors from genetic to molecular level.
Ayub A, Ashfaq U, Haque A
Biomed Res Int. 2013; 2013:810461.
PMID: 23991421
PMC: 3749539.
DOI: 10.1155/2013/810461.
Hepatorenal tyrosinemia.
Kitagawa T
Proc Jpn Acad Ser B Phys Biol Sci. 2012; 88(5):192-200.
PMID: 22687740
PMC: 3410490.
DOI: 10.2183/pjab.88.192.